Leonard B. Seeff

TL;DR: Intended for use by physicians, these recommendations suggest preferred approaches to the diagnostic, therapeutic and preventive aspects of care to be flexible, in contrast to standards of care, which are inflexible policies to be followed in every case.

TL;DR: In this paper, the authors provided varying estimates of the risk of progression in chronic hepatitis C. The combined population data indicated that the disease progresses slowly over approximately 30 years, on average.

TL;DR: The identification of hepatitis C virus (HCV) as the cause of non-A, non-B hepatitis represents a technical tour de force of modern molecular medicine and has led to a better understanding of the viral life cycle and the pathogenesis of HCV-associated disease.

TL;DR: The view is concluded that severe, life-threatening, progressive liver disease clearly occurs in a sizable minority of chronically infected persons but it is speculated that fibrosis progression is neither linear or inevitable and hence that most hepatitis C virus carriers will have either a stable nonprogressive course or such indolent progression that they will die from an unrelated disease before the severe sequelae of hepatitis C become manifest.